News

Venture Investors of Madison, Wisconsin, with participation by Black Mountain Ventures of Foster City, California, led the investment. The company will use the funding to refine product development

Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures; as sole and adjunct therapy for patients

The results demonstrated from the study indicated that QFT had a predictive value for developing TB disease of 15%, more than 6 times greater than the 2.3% for

The Phase I clinical trial, designed as a dose-escalation study to test the safety of NP2 will be conducted at the University of Michigan in Ann Arbor. In

The purpose of the study is to evaluate the effectiveness and clinical outcomes of Memo 3D when used to repair a diseased or dysfunctional mitral valve. The open

Under the terms of the transaction, company plans to acquire all the assets of Ion Metrics, including its mass spectrometer (MS) technology, differential mobility spectrometer (DMS) technology, ion

The trial will evaluate the efficacy and safety of INGN 225 in as many as 80 patients with extensive stage SCLC at multiple centers. Patients with SCLC have

The new equity investments were made by existing investors, including New Enterprise Associates, National Healthcare Services, Red River Ventures and Chisholm Private Capital. The debt financing was provided

Currently, Rich Whitney is founder and managing member of Whitney Capital and also serves as a Venture Partner with New Enterprise Associates. Previously, Mr.Whitney served as CFO of